Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia
Authors' conclusion
Low-dose sulfonylurea plus DPP4i has a potent glucose-lowering effect through augmentation of beta-cell function. A double-blind randomized controlled trial would formalize efficacy and safety of this combination, which may avoid negative aspects of SU.
Study context
- Population
- People with T2D (HbA1c <64 mmol/mol) treated with diet or metformin; Clinical Research Centre, University of Dundeecrossover, 4 blocks
- Participants
- 30 people
- Comparison
- Low-dose gliclazide, sitagliptin and their combination vs control
- Primary endpoint
- Beta-cell glucose sensitivity (mixed meal test after each intervention)
Methodological detailsunblinded, single-centre
- Unblinded
- Single-centre
Primary result
As reported in the abstract
Glucose sensitivity (pmol min-1 m-2 mM-1)
P = 0.04
Secondary outcomes
Mean glucose AUC — SUDPP4i vs Control · across the 4 treatments; additive effect on glucose lowering
P < 0.001
Additive effect by gender
- The additive effect was seen in men but not women
Safety
Glucose time <3 mmol/L on CGM (%) — SUDPP4i vs Control · unaffected across treatments
P = 0.65
Original publication
Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia. J Clin Endocrinol Metab. Published 24 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →